

IMPROVED CD4-IgG2 FORMULATIONS

Abstract of the Invention

5 This invention provides formulations of the anti-HIV
therapeutic, CD4-IgG2, that contain higher concentrations of
the therapeutic than were previously prepared, are stable,
compatible with lyophilization, and safe to administer. These
formulations are suitable for intravenous, subcutaneous and
10 intramuscular delivery, the latter two routes being
potentially useful for facilitating self-administration by
HIV-infected individuals. This invention is also directed to
methods of making the CD4-IgG2 formulations described in the
disclosure, and methods of using the formulations to inhibit
15 or prevent infect CD4+ cells from becoming infected with HIV,
and to treat subjects having CD4+ cells infected with HIV.